Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study) Martin, Allison, Smith, Don, Carr, Andrew, Hoy, Jennifer, Chuah, John, Mallal, Simon, Law, Matthew, Clements, Mark, Cooper, David A., Wheatley, D., Austin, David and The PIILR Study Group 2004, Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study), HIV clinical trials, vol. 5, no. 4, pp. 192-200, doi: 10.1310/0GU7-6X27-MMHE-5ALE. Attached Files Name Description MIMEType Size Downloads Title Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study) Author(s) Martin, Allison Smith, Don Carr, Andrew Hoy, Jennifer Chuah, John Mallal, Simon Law, Matthew Clements, Mark Cooper, David A. Wheatley, D. Austin, David orcid.org/0000-0002-1296-3555 The PIILR Study Group Journal name HIV clinical trials Volume number 5 Issue number 4 Start page 192 End page 200 Total pages 9 Publisher Taylor & Francis Place of publication Abingdon, Eng Publication date 2004-07 ISSN 1528-4336 Keyword(s) PIILR Study Group Summary Purpose: During the 24-week PIILR study of protease inhibitor (PI) withdrawal, improved lipids and reduction in intraabdominal visceral fat was seen, however, there was also a loss of subcutaneous limb fat in patients with HIV-lipodystrophy (LD). It was hypothesized that overall improvement in LD may require a longer period of time off Pls. Method: Follow-up of patients randomized to stop or continue PI-based therapy for 24 weeks, in a multicenter study, was continued for up to 120 weeks. Biochemistry and lipid parameters were assessed every 3 months. DEXA and CT scans were performed annually. Limb fat, visceral adipose tissue, and the lipodystrophy case definition score (LCDS) were used as indicators of LD severity. Results: Forty-five male patients with baseline and week 120 body composition data were assessed. There were no significant changes in the limb fat or visceral adipose tissue (VAT) components of LD, with the exception of the LCDS (change from baseline +5.79, p < .001). Control of viral replication was maintained and lipid and glycemic parameters were unchanged over the 120-week follow-up. Linear regression analysis showed on-study usage of stavudine was independently and significantly correlated with both decreased limb fat mass and a higher LCDS. Conclusion: Body composition or metabolic features of LD did not improve over 2 years of observation in patients remaining on predominantly PI-sparing therapy. LD was adversely influenced by continued stavudine use. © 2004 Thomas Land Publishers, Inc. Language eng DOI 10.1310/0GU7-6X27-MMHE-5ALE Indigenous content off Field of Research 1103 Clinical Sciences HERDC Research category C1.1 Refereed article in a scholarly journal Copyright notice ©2004, Thomas Land Publishers, Inc Persistent URL http://hdl.handle.net/10536/DRO/DU:30126863 Document type: Journal Article Collections: Faculty of Health PVC's Office - Health Related Links Link Description Connect to published version Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Thu, 18 Jul 2019, 13:57:18 EST Fri, 19 Jul 2019, 05:05:42 EST Fri, 19 Jul 2019, 06:13:16 EST Thu, 19 Sep 2019, 11:51:55 EST Thu, 19 Sep 2019, 11:54:57 EST Thu, 19 Sep 2019, 11:56:21 EST Filtered Full Citation counts:   Cited 0 times in TR Web of Science Cited 14 times in Scopus Search Google Scholar Access Statistics: 83 Abstract Views, 0 File Downloads  -  Detailed Statistics Created: Thu, 18 Jul 2019, 13:57:18 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.